Inivata to Present New Clinical Data on the Utility of the InVision® Liquid Biopsy Platform in Advanced Non-Small Cell Lung Cancer (NSCLC) at WCLC 2018

Oral presentations and posters to feature Inivata’s InVisionFirst™ -Lung and the applications of liquid biopsy in Advanced Non-Small Cell Lung Cancer

Inivata, a leader in liquid biopsy announces that the Company and its world-leading collaborators will showcase cutting-edge data in two mini oral presentations and six posters at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer (WCLC) 23 – 26 September in Toronto. The details are as follows:

Presentation: Feasibility, clinical relevance of ALK/ROS1 fusion variant detection by liquid biopsy in advanced non-small cell lung cancer (MA16.09)
Date and time: September 25, 13.30-15.00
Location: Room 203BD
For the list of authors, click here

 Presentation: Prospective clinical validation of the InVisionFirst™ ctDNA assay for molecular profiling of patients with advanced NSCLC (MA16.02)
Date and time: September 25, 13.30-15.00
Location: Room 203BD
For the list of authors, click here

Poster: Multicentre phase II trial of first-line afatinib in patients with suspected/confirmed EGFR mutant NSCLC: ctDNA and long-term efficacy (P1.13-17)
Date and time: September 24, 9.45-10.30 and 16.45-18.00
Location: Exhibition Hall
For the list of authors, click here

Poster: Circulating tumor DNA analysis for predicting response to osimertinib and disease progression in EGFR-mutant non-small-cell lung cancer (NSCLC) (P1.01-46)
Date and time: September 24, 9.45-10.30 and 16.45-18.00
Location: Exhibition Hall
For the list of authors, click here

Poster: Clinical relevance of ALK/ROS1 resistance mutations and other acquired mutations detected by liquid biopsy in advanced NSCLC patients (P1.01-67)
Date and time: September 24, 9.45-10.30 and 16.45-18.00
Location: Exhibition Hall
For the list of authors, click here

Poster: Validation of InVisionFirst ctDNA NGS profiling via ddPCR testing in patients with Non-Small cell lung cancer (NSCLC) (P2.01-78)
Date and time: September 25, 9.45-10.30 and 16.45-18.00
Location: Exhibition Hall
For the list of authors, click here

Poster: Prospective efficacy of osimertinib in circulating tumour DNA (ctDNA) T790M-mutant NSCLC patients (P2.13-24)
Date and time: September 25, 9.45-10.30 and 16.45-18.00
Location: Exhibition Hall
For the list of authors, click here

Poster: Early plasma ctDNA response anticipates clinical response to first-line immunotherapy in advanced NSCLC (P3.04-02)
Date and time: September 26, 9.45-10.30 and 12.00-13.30
Location: Exhibition Hall
For the list of authors, click here